Stay updated on BMS-986205 Combo with Nivolumab in Chinese Patients Clinical Trial
Sign up to get notified when there's something new on the BMS-986205 Combo with Nivolumab in Chinese Patients Clinical Trial page.

Latest updates to the BMS-986205 Combo with Nivolumab in Chinese Patients Clinical Trial page
- Check3 days agoChange DetectedRevision history updated: added v3.4.3 and removed v3.4.2.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedNo significant changes detected; core study information remains the same.SummaryDifference0.1%

- Check31 days agoChange DetectedAdded a new site revision tag: Revision: v3.4.2, and removed the older Revision: v3.4.1 along with a government funding status notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check38 days agoChange DetectedAdded a site-wide notice about funding-related data delays with links for status updates. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check46 days agoChange DetectedAdded a 'Show glossary' option and introduced a 'Last Update Submitted that Met QC Criteria' field along with a 'Revision: v3.4.0' label. The previous items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check60 days agoChange DetectedRevision: v3.3.4 appears on the page, replacing the previous v3.3.3; this reflects a minor metadata update with no visible changes to study content. No edits to core sections such as study results, eligibility criteria, or endpoints are detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to BMS-986205 Combo with Nivolumab in Chinese Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BMS-986205 Combo with Nivolumab in Chinese Patients Clinical Trial page.